• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与智障老年人多重用药和过度多重用药相关的因素与普通人群不同:一项全国性横断面观察研究。

Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study.

作者信息

O'Dwyer Máire, Peklar Jure, McCallion Philip, McCarron Mary, Henman Martin C

机构信息

School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland IDS-TILDA School of Nursing and Midwifery, Trinity College Dublin, Dublin, Ireland.

School of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.

出版信息

BMJ Open. 2016 Apr 4;6(4):e010505. doi: 10.1136/bmjopen-2015-010505.

DOI:10.1136/bmjopen-2015-010505
PMID:27044582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4823458/
Abstract

OBJECTIVES

(1) To evaluate the prevalence of polypharmacy (5-9 medicines) and excessive polypharmacy (10+ medicines) and (2) to determine associated demographic and clinical characteristics in an ageing population with intellectual disabilities (IDs).

DESIGN

Observational cross-sectional study.

SETTING

Wave One (2009/2010) of the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS-TILDA).

PARTICIPANTS

A nationally representative sample of 753 persons with ID, aged between 41 and 90 years. Participants/proxy reported medicines (prescription and over the counter) taken on a regular basis; medication data was available for 736 participants (98%).

MAIN OUTCOME MEASURES/INTERVENTIONS: Participants were divided into those with no polypharmacy (0-4 medicines), polypharmacy (5-9 medicines) and excessive polypharmacy (10+ medicines). Medication use patterns were analysed according to demographic variables and reported chronic conditions. A multinomial logistic regression model identified factors associated with polypharmacy (5-9 medicines) and excessive polypharmacy (≥10 medicines).

RESULTS

Overall, 90% of participants reported use of medicines. Polypharmacy was observed in 31.5% of participants and excessive polypharmacy in 20.1%. Living in a residential institution, and reporting a mental health or neurological condition were strongly associated with polypharmacy and excessive polypharmacy after adjusting for confounders, but age or gender had no significant effect.

CONCLUSIONS

Polypharmacy was commonplace for older adults with ID and may be partly explained by the high prevalence of multimorbidity reported. Review of appropriateness of medication use is essential, as polypharmacy places ageing people with ID at risk of adverse effects.

摘要

目的

(1)评估多重用药(5 - 9种药物)和过度多重用药(10种及以上药物)的患病率;(2)确定老年智力残疾人群的相关人口统计学和临床特征。

设计

观察性横断面研究。

背景

爱尔兰老龄化纵向研究(IDS - TILDA)的智力残疾补充研究的第一波(2009/2010年)。

参与者

753名年龄在41至90岁之间、具有全国代表性的智力残疾者样本。参与者/代理人报告了定期服用的药物(处方药和非处方药);736名参与者(98%)有用药数据。

主要结局指标/干预措施:参与者被分为无多重用药(0 - 4种药物)、多重用药(5 - 9种药物)和过度多重用药(10种及以上药物)组。根据人口统计学变量和报告的慢性病分析用药模式。多分类逻辑回归模型确定与多重用药(5 - 9种药物)和过度多重用药(≥10种药物)相关的因素。

结果

总体而言,90%的参与者报告使用药物。31.5%的参与者存在多重用药情况,20.1%存在过度多重用药情况。在校住机构生活且报告有心理健康或神经疾病与多重用药和过度多重用药在调整混杂因素后密切相关,但年龄或性别无显著影响。

结论

多重用药在老年智力残疾者中很常见,部分原因可能是所报告的多种疾病的高患病率。审查用药的适宜性至关重要,因为多重用药使老年智力残疾者面临不良反应风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed5/4823458/aa720af875e7/bmjopen2015010505f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed5/4823458/7ac8518471f2/bmjopen2015010505f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed5/4823458/aa720af875e7/bmjopen2015010505f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed5/4823458/7ac8518471f2/bmjopen2015010505f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed5/4823458/aa720af875e7/bmjopen2015010505f02.jpg

相似文献

1
Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study.与智障老年人多重用药和过度多重用药相关的因素与普通人群不同:一项全国性横断面观察研究。
BMJ Open. 2016 Apr 4;6(4):e010505. doi: 10.1136/bmjopen-2015-010505.
2
Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland.爱尔兰智障老年人群体中心理治疗类药物的使用现状、模式及相关因素分析。
J Intellect Disabil Res. 2017 Oct;61(10):969-983. doi: 10.1111/jir.12391. Epub 2017 Jun 21.
3
Medication burden and frailty in older adults with intellectual disability: An observational cross-sectional study.患有智力障碍的老年人的药物负担和脆弱性:一项观察性横断面研究。
Pharmacoepidemiol Drug Saf. 2020 Apr;29(4):482-492. doi: 10.1002/pds.4987. Epub 2020 Mar 5.
4
Medication and supplement use in older people with and without intellectual disability: An observational, cross-sectional study.有和没有智力障碍的老年人的药物和补充剂使用情况:一项观察性横断面研究。
PLoS One. 2017 Sep 6;12(9):e0184390. doi: 10.1371/journal.pone.0184390. eCollection 2017.
5
Prevalence and patterns of anti-epileptic medication prescribing in the treatment of epilepsy in older adults with intellectual disabilities.老年智力障碍癫痫患者抗癫痫药物治疗的流行情况和模式。
J Intellect Disabil Res. 2018 Mar;62(3):245-261. doi: 10.1111/jir.12461. Epub 2018 Jan 5.
6
Patterns of multimorbidity in an older population of persons with an intellectual disability: results from the intellectual disability supplement to the Irish longitudinal study on aging (IDS-TILDA).智障人群中老年人群的多重疾病模式:来自爱尔兰老龄化纵向研究(IDS-TILDA)智力障碍补充研究的结果。
Res Dev Disabil. 2013 Jan;34(1):521-7. doi: 10.1016/j.ridd.2012.07.029. Epub 2012 Oct 17.
7
Health and Health-Care Utilization of the Older Population of Ireland: Comparing the Intellectual Disability Population and the General Population.爱尔兰老年人口的健康状况与医疗保健利用情况:智障人群与普通人群的比较
Res Aging. 2017 Jul;39(6):693-718. doi: 10.1177/0164027516684172.
8
Drug burden index to define the burden of medicines in older adults with intellectual disabilities: An observational cross-sectional study.药物负担指数定义智力障碍老年患者的药物负担:一项观察性横断面研究。
Br J Clin Pharmacol. 2018 Mar;84(3):553-567. doi: 10.1111/bcp.13479. Epub 2018 Jan 5.
9
Prescription errors in older individuals with an intellectual disability: prevalence and risk factors in the Healthy Ageing and Intellectual Disability Study.智障老年人的处方错误:在健康老龄化和智障研究中的流行率和风险因素。
Res Dev Disabil. 2013 May;34(5):1656-62. doi: 10.1016/j.ridd.2013.02.005. Epub 2013 Mar 15.
10
Central nervous system medication use in older adults with intellectual disability: Results from the successful ageing in intellectual disability study.智障老年人的中枢神经系统药物使用情况:智障者成功老龄化研究的结果
Aust N Z J Psychiatry. 2016 Apr;50(4):352-62. doi: 10.1177/0004867415587951. Epub 2015 May 27.

引用本文的文献

1
Exploring how Japanese pharmacists provide reasonable accommodations for persons with intellectual disabilities.探索日本药剂师如何为智障人士提供合理便利。
BMC Health Serv Res. 2025 Jul 3;25(1):913. doi: 10.1186/s12913-025-13035-7.
2
Intellectual or developmental disabilities and curative female breast cancer treatment: A population-based retrospective cohort study.智力或发育障碍与女性乳腺癌根治性治疗:一项基于人群的回顾性队列研究。
Breast. 2025 May 27;82:104509. doi: 10.1016/j.breast.2025.104509.
3
Polypharmacy Prevalence Among Older Adults Based on the Survey of Health, Ageing and Retirement in Europe: An Update.

本文引用的文献

1
Prevalence and factors associated with polypharmacy in Victorian adults with intellectual disability.维多利亚州成年智障者多重用药的患病率及相关因素
Res Dev Disabil. 2014 Nov;35(11):3071-80. doi: 10.1016/j.ridd.2014.07.060. Epub 2014 Aug 15.
2
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.加强观察性研究在流行病学中的报告 (STROBE):解释和说明。
Int J Surg. 2014 Dec;12(12):1500-24. doi: 10.1016/j.ijsu.2014.07.014. Epub 2014 Jul 18.
3
Lessons learned from our elders: how to study polypharmacy in populations with intellectual and developmental disabilities.
基于欧洲健康、老龄化与退休调查的老年人多重用药患病率:最新情况
J Clin Med. 2025 Feb 17;14(4):1330. doi: 10.3390/jcm14041330.
4
Inappropriate medication prescribing, polypharmacy, potential drug-drug interactions and medication regimen complexity in older adults attending three referral hospitals in Asmara, Eritrea: a cross-sectional study.厄立特里亚阿斯马拉三家转诊医院老年患者不适当用药处方、多重用药、潜在药物相互作用及用药方案复杂性:一项横断面研究
BMC Geriatr. 2025 Feb 3;25(1):76. doi: 10.1186/s12877-025-05736-9.
5
Adverse drug reactions and events in an Ageing PopulaTion risk Prediction (ADAPTiP) tool: the development and validation of a model for predicting adverse drug reactions and events in older patients.老年人群药物不良反应及事件风险预测(ADAPTiP)工具:一种预测老年患者药物不良反应及事件模型的开发与验证
Eur Geriatr Med. 2025 Apr;16(2):573-581. doi: 10.1007/s41999-024-01152-1. Epub 2025 Jan 17.
6
Cognitive impairment predicts medication discrepancies in Huntington's Disease: patient self-report compared to pharmacy records.认知障碍可预测亨廷顿舞蹈症患者的用药差异:患者自我报告与药房记录的比较
J Neurol. 2024 Dec 12;272(1):55. doi: 10.1007/s00415-024-12728-z.
7
Investigating pain-related medication use and contribution to polypharmacy in adults with intellectual disabilities: a systematic review.调查成年智力残疾患者中与疼痛相关的药物使用情况及其对多重用药的影响:一项系统综述。
BMC Med. 2024 Dec 2;22(1):565. doi: 10.1186/s12916-024-03770-9.
8
Preliminary guidelines for the detection and management of drug-related problems in cancer patients with type 2 diabetes mellitus: a practical resource for oncology pharmacists.癌症合并 2 型糖尿病患者药物相关问题的检测与管理初步指南:肿瘤药师实用资源
Support Care Cancer. 2024 Nov 14;32(12):791. doi: 10.1007/s00520-024-09014-z.
9
Medication Management in Portuguese Long-Term Care Facilities: A Preliminary Cross-Sectional Study.葡萄牙长期护理机构中的药物管理:一项初步横断面研究。
Healthcare (Basel). 2024 Oct 29;12(21):2145. doi: 10.3390/healthcare12212145.
10
Medication Use and Treatment Indications in Huntington's Disease; Analyses from a Large Cohort.亨廷顿舞蹈症的药物使用与治疗指征;来自一个大型队列的分析
Mov Disord Clin Pract. 2024 Dec;11(12):1530-1541. doi: 10.1002/mdc3.14230. Epub 2024 Oct 21.
从我们的长辈身上吸取的教训:如何在智力和发育障碍人群中研究多种药物疗法。
Intellect Dev Disabil. 2014 Feb;52(1):60-77. doi: 10.1352/1934-9556-52.1.60.
4
Multimorbidity in older adults with intellectual disabilities.患有智力障碍的老年人中的多种疾病共存情况。
Res Dev Disabil. 2014 Apr;35(4):776-83. doi: 10.1016/j.ridd.2014.01.022. Epub 2014 Feb 14.
5
Medication use among Australian adults with intellectual disability in primary healthcare settings: a cross-sectional study.澳大利亚初级医疗保健机构中成年智障患者的药物使用情况:一项横断面研究。
J Intellect Dev Disabil. 2013 Jun;38(2):177-81. doi: 10.3109/13668250.2013.778968. Epub 2013 Apr 3.
6
Polypharmacy in nursing home residents with severe cognitive impairment: results from the SHELTER Study.疗养院中严重认知障碍的老年患者的多重用药:SHELTER 研究结果。
Alzheimers Dement. 2013 Sep;9(5):587-93. doi: 10.1016/j.jalz.2012.09.009. Epub 2012 Dec 8.
7
Patterns of multimorbidity in an older population of persons with an intellectual disability: results from the intellectual disability supplement to the Irish longitudinal study on aging (IDS-TILDA).智障人群中老年人群的多重疾病模式:来自爱尔兰老龄化纵向研究(IDS-TILDA)智力障碍补充研究的结果。
Res Dev Disabil. 2013 Jan;34(1):521-7. doi: 10.1016/j.ridd.2012.07.029. Epub 2012 Oct 17.
8
Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.共病的流行病学及其对医疗保健、研究和医学教育的影响:一项横断面研究。
Lancet. 2012 Jul 7;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2. Epub 2012 May 10.
9
Primary care of adults with developmental disabilities: Canadian consensus guidelines.成人发育障碍的初级保健:加拿大共识指南。
Can Fam Physician. 2011 May;57(5):541-53, e154-68.
10
Ageing and health status in adults with intellectual disabilities: results of the European POMONA II study.成年智力残疾者的衰老与健康状况:欧洲波莫纳二世研究结果
J Intellect Dev Disabil. 2011 Mar;36(1):49-60. doi: 10.3109/13668250.2010.549464.